Head to Head Contrast: INmune Bio (NASDAQ:INMB) vs. Pulmatrix (NASDAQ:PULM)

INmune Bio (NASDAQ:INMB) and Pulmatrix (NASDAQ:PULM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for INmune Bio and Pulmatrix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2	2	2	1	2.29
Pulmatrix	1	0	0	0	1.00

INmune Bio presently has a consensus price target of $18.00, suggesting a potential upside of 1,025.00%. Given INmune Bio’s stronger consensus rating and higher possible upside, analysts plainly believe INmune Bio is more favorable than Pulmatrix.

Insider & Institutional Ownership

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 21.0% of INmune Bio shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

INmune Bio has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Profitability

This table compares INmune Bio and Pulmatrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-115.06%	-89.95%
Pulmatrix	N/A	-94.13%	-85.42%

Valuation and Earnings

This table compares INmune Bio and Pulmatrix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$10,000.00	4,252.80	-$42.08 million	($2.12)	-0.75
Pulmatrix	$7.81 million	N/A	-$9.56 million	($1.70)	-1.56

Pulmatrix has higher revenue and earnings than INmune Bio. Pulmatrix is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Summary

INmune Bio beats Pulmatrix on 7 of the 13 factors compared between the two stocks.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.